Michael Gschwantler
Overview
Explore the profile of Michael Gschwantler including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
81
Citations
1334
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Razavi H, Waked I, Qureshi H, Kondili L, Duberg A, Aleman S, et al.
J Hepatol
. 2025 Feb;
PMID: 39914746
Background And Aims: The year 2023 marked the 10-year anniversary of the launch of direct-acting antivirals (DAAs) for the treatment of the hepatitis C virus (HCV). HCV treatment trends by...
2.
Semmler G, Alonso Lopez S, Pons M, Lens S, Dajti E, Griemsmann M, et al.
Hepatology
. 2025 Jan;
81(2):609-624.
PMID: 39817915
Background And Aims: Around 750,000 patients per year will be cured of HCV infection until 2030. Those with compensated advanced chronic liver disease remain at risk for hepatic decompensation and...
3.
Balcar L, Schwarz M, Dorn L, Jachs M, Hartl L, Weseslindtner L, et al.
Liver Int
. 2024 Oct;
44(12):3151-3163.
PMID: 39351692
Background And Aims: Identification of people living with hepatitis C virus (HCV) via readily available laboratory records could be a key strategy for macro-elimination, aligning with the WHO elimination goal....
4.
Burghart L, Ferenci P, Petrenko O, Mandorfer M, Schwarz M, Gschwantler M, et al.
Aliment Pharmacol Ther
. 2024 May;
60(2):257-266.
PMID: 38798050
Background And Aims: Wilson's disease may progress to cirrhosis and clinically significant portal hypertension (CSPH). We aimed to assess the prevalence and prognostic impact of CSPH-related features on hepatic decompensation...
5.
Semmler G, Alonso Lopez S, Pons M, Lens S, Dajti E, Griemsmann M, et al.
J Hepatol
. 2024 Mar;
81(1):76-83.
PMID: 38521170
Background & Aims: Baveno VII has defined a clinically significant (i.e., prognostically meaningful) decrease in liver stiffness measurement (LSM) in cACLD as a decrease of ≥20% associated with a final...
6.
Schwarz C, Bauer D, Dorn L, Jachs M, Hartl L, Chromy D, et al.
Wien Klin Wochenschr
. 2023 Sep;
136(9-10):278-288.
PMID: 37773541
Background And Aims: Micro-elimination projects targeted to specific hepatitis C virus (HCV) risk populations have been successful. Systematic identification of persons with HCV viremia, regardless of risk group, based on...
7.
Schwarz C, Schubert R, Schwarz M, Schutz A, Jenke A, Bauer D, et al.
J Virus Erad
. 2023 Sep;
9(3):100338.
PMID: 37663576
Background: Hepatitis C remains highly prevalent among people who inject drugs (PWIDs). We propose an integrated approach for screening/diagnostic testing and treatment in 6,665 Viennese PWIDs registered to access opioid...
8.
Schwarz M, Schwarz C, Burghart L, Pfisterer N, Bauer D, Hubl W, et al.
PLoS One
. 2023 Aug;
18(8):e0290352.
PMID: 37616205
Introduction: Liver cirrhosis accounts for considerable morbidity and mortality worldwide and late presentation limits therapeutic options. We aimed to assess characteristics of patients with liver cirrhosis at the time of...
9.
Schwarz C, Schmidbauer V, Lagler H, Stremitzer S, Kaczirek K, Langenberger H, et al.
J Travel Med
. 2023 Aug;
30(6).
PMID: 37565821
No abstract available.
10.
Mandorfer M, Aigner E, Cejna M, Ferlitsch A, Datz C, Grater T, et al.
Wien Klin Wochenschr
. 2023 Jun;
135(Suppl 3):493-523.
PMID: 37358642
The Billroth IV consensus was developed during a consensus meeting of the Austrian Society of Gastroenterology and Hepatology (ÖGGH) and the Austrian Society of Interventional Radiology (ÖGIR) held on the...